Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Optimal CD4 count for initiating HIV treatment: impact of CD4 observation frequency and grace periods, and performance of dynamic marginal structural models.

Ewings FM, Ford D, Walker AS, Carpenter J, Copas A.

Epidemiology. 2014 Mar;25(2):194-202. doi: 10.1097/EDE.0000000000000043.

2.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration., Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

3.

Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.

Chang LW, Harris J, Humphreys E.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008494. doi: 10.1002/14651858.CD008494. Review.

PMID:
20393969
4.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
5.

Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.

Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA; Cost-Effectiveness of Preventing AIDS Complications Investigators..

Antivir Ther. 2005;10(1):41-52.

PMID:
15751762
6.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
7.

An evaluation of antiretroviral HIV/AIDS treatment in a Rio de Janeiro public clinic.

Carmody ER, Diaz T, Starling P, dos Santos AP, Sacks HS.

Trop Med Int Health. 2003 May;8(5):378-85.

8.

Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic.

Easterbrook PJ, Yu LM, Goetghebeur E, Boag F, McLean K, Gazzard B.

AIDS. 2000 Mar 31;14(5):561-71.

PMID:
10780719
9.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
10.

Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.

Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR.

J Infect Dis. 2007 Feb 1;195(3):425-31.

11.

Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study.

Franke MF, Robins JM, Mugabo J, Kaigamba F, Cain LE, Fleming JG, Murray MB.

PLoS Med. 2011 May;8(5):e1001029. doi: 10.1371/journal.pmed.1001029.

12.

[Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters].

Pérez-Hoyos S, Ferreros I, Hernán MA; GEMES..

Gac Sanit. 2007 Jan-Feb;21(1):76-83. Spanish.

13.

Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD004772. doi: 10.1002/14651858.CD004772.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;(5):CD004772.

PMID:
22786492
14.

Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy.

Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, Hulgan T, Sterling TR.

Epidemiology. 2010 Sep;21(5):698-705. doi: 10.1097/EDE.0b013e3181e97737.

15.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV..

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
16.

Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.

Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M.

Cochrane Database Syst Rev. 2013 Oct 10;(10):CD010309. doi: 10.1002/14651858.CD010309.pub2. Review.

17.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
18.

CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group.

Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT.

AIDS. 1998 Oct 1;12(14):1823-32.

PMID:
9792383
19.

Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study.

Maskew M, Fox MP, van Cutsem G, Chu K, Macphail P, Boulle A, Egger M, Africa FI.

PLoS One. 2013 Jun 5;8(6):e64392. doi: 10.1371/journal.pone.0064392.

20.

A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.

Phanuphak P, Grayson ML, Sirivichayakul S, Suwanagool S, Ruxrungtham K, Hanvanich M, Ratanasuwan W, Ubolyam S, Hughes MD, Wanke CA, Hammer SM.

Aust N Z J Med. 2000 Feb;30(1):11-20.

PMID:
10800872
Items per page

Supplemental Content

Support Center